What nephrology is researching now
The topics gaining the most ground, ranked by the PubDaily Trend Score: new research, stronger evidence, new trials and new guidelines. 291 topics in 22 specialties, updated 18 Oct 2026.
Monthly reportThe fastest-rising topics in medicine: October 2026Read →GLP-1 drugs in kidney disease
GLP-1 based medicines and kidney outcomes.
Key point: In CKD, GLP-1 receptor agonists were associated with fewer major adverse kidney events and lower albuminuria, primarily in type 2 diabetes, with gastrointestinal concerns.
SGLT2 inhibitors in CKD
SGLT2 inhibitors to slow chronic kidney disease.
Key point: In non-diabetic CKD, renin-angiotensin system inhibitors and SGLT2 inhibitors would be indicated as the treatment of choice.
Acute kidney injury biomarkers
Biomarkers to detect and predict acute kidney injury.
IgA nephropathy
IgA nephropathy and the new targeted treatments being studied.
Lupus nephritis
Kidney involvement in lupus and its newer treatments.
Key point: Lupus nephritis management is increasingly individualized, with expanding treatment options, combination therapy, and a trend toward lower corticosteroid doses.
Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point: Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
See all 12 nephrology topics
Every rising topic, with the papers behind it. Free for doctors.
How the Trend Score works
Four signals
Growth in new papers (35%), growth in randomised trials, meta-analyses and systematic reviews (25%), new clinical trials registered (20%), and new guidelines and consensus statements (20%), each over the last 12 months against the 12 before.
A score out of 100
Each signal is ranked against every topic we follow, so a score of 90 means the topic is ahead of about 90% of them. Rising fast: 80 and above. Rising: 55 to 79. Emerging: fewer than 100 papers the year before, too few to rank.
What it does not tell you
More research on a topic is not evidence that a treatment works. Open a topic to read the papers and guidelines themselves. Counts come from PubMed and ClinicalTrials.gov.